CSL Ltd ( ASX: CSL) shares will be closely watched by Aussie investors next week. That's because the biotechnology giant is ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL (CMXHF – Research Report) on January 29 and set a price target of A$286.00.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...

While Trump has not yet specifically targeted imports from Australia, his offensive has profoundly destabilising economic and ...

It isn't as hard as you might think to build a world class ASX share portfolio in 2025. Here's what you need to ...

Joe McCarthy from Elston and David Wilson from First Sentier run the ruler over your most-tipped growth stocks for 2025 ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

The pressure is on the Albanese government to negotiate the same deal the Turnbull government did in 2018, which exempted ...

Australia's CSL has said its one-monthly treatment for ... other drugs used to prevent attacks in HAE, including Takeda's plasma kallikrein inhibitor Takhzyro (lanadelumab), which is dosed once ...

Shares in export-oriented companies from healthcare to retail crashed on Monday as the US president vowed to expand his trade ...

CSL has fleshed out the data from its phase 3 ... The results compare well with plasma kallikrein inhibitor Takhzyro (lanadelumab) in HAE, which is given by subcutaneous injection every two ...